July 2015 tender notification
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2014/15 Invitation to Tender, dated 6 November 2014.
Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms and Pharmacodes
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the 12th of the month prior to the date of subsidy change. More information and NOPC forms can be found on our website.
Where a product does not have a current Pharmacode, suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand before the 12th of the month prior to the date of listing. PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.
2014/15 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2018
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
| Chemical name | Presentation; Pack size and type |
Current subsidy (and price) | New subsidy (and price) | Sole supply brand (Supplier) |
Date of subsidy change | Sole Subsidised Supply date |
|---|---|---|---|---|---|---|
| Nevirapine | Tab 200 mg; 60 tablets, bottle pack |
$95.94 | $65.00 | Nevirapine Alphapharm (Mylan) |
1 September 2015 | 1 December 2015 |
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
| Chemical name | Presentation; Pack size and type |
Current subsidy (and price) |
New subsidy (and price) |
Hospital Supply Brand (Supplier) |
DV Limit |
Date of subsidy change | Hospital Supply Status date |
|---|---|---|---|---|---|---|---|
| Idarubicin hydrochloride 1 | Inj 5 mg vial; 1 vial |
$100.00 | $125.00 | Zavedos (Pfizer) |
1% | 1 September 2015 | 1 November 2015 |
| Idarubicin hydrochloride 1 | Inj 10 mg vial; 1 vial |
$200.00 | $250.00 | Zavedos (Pfizer) |
1% | 1 September 2015 | 1 November 2015 |
| Nevirapine | Tab 200 mg; 60 tablets, bottle pack |
$95.94 | $65.00 | Nevirapine Alphapharm (Mylan) |
1% | 1 September 2015 | 1 November 2015 |
|
|||||||
Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
| Chemical name | Presentation; Pack size and type |
Current subsidy (and price) |
New subsidy (and price) |
Hospital Supply Brand (Supplier) |
DV Limit | Listing date | Hospital Supply Status date |
Brand (Supplier) |
|---|---|---|---|---|---|---|---|---|
| Cisplatin 1 | Inj 1 mg per ml, 50 ml vial; 1 vial |
$15.00 | $12.29 | DBL Cisplatin (Hospira) |
1% | 1 September 2015 | 1 November 2015 | Cisplatin Ebewe (Sandoz) |
| Cisplatin 1 | Inj 1 mg per ml, 100 ml vial; 1 vial |
$21.00 | $22.46 | DBL Cisplatin (Hospira) |
1% | 1 September 2015 | 1 November 2015 | Cisplatin Ebewe (Sandoz) |
| Oxaliplatin 2 | Inj 5 mg per ml, 10 ml vial; 1 vial |
$15.32 | $13.32 | Oxaliccord (Actavis) |
1% | 1 January 2016 | 1 March 2016 | Oxaliplatin Actavis (Actavis) |
| Oxaliplatin 2 | Inj 5 mg per ml, 20 ml vial; 1 vial |
$25.01 | $16.00 | Oxaliccord (Actavis) |
1% | 1 January 2016 | 1 March 2016 | Oxaliplatin Actavis (Actavis) |
|
||||||||
Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status
PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in the 2013/14 Invitation to Tender, dated 7 November 2013, and the 2014/15 Invitation to Tender, dated 6 November 2014:
2013/14 Invitation to Tender
| Chemical name | Line item |
|---|---|
| Omeprazole | Inf 40 mg |
| Omeprazole | Inj 40 mg |
2014/15 Invitation to Tender
| Chemical name | Line Item |
|---|---|
| Condoms | 51 mm or less (nominal width) |
| Condoms | 52 mm - 54 mm (nominal width) |
| Condoms | 55 mm - 58 mm (nominal width) |
| Condoms | 59 mm or greater (nominal width) |
| Condoms | Female condom |
| Condoms | Flavoured 54 mm or less (nominal width) |
| Condoms | Flavoured 55 mm or greater (nominal width) |
| Medical lubricated jelly | <200 ml |
| Pegylated liposomal doxorubicin | Inj 20 mg |
| Pegylated liposomal doxorubicin | Inj 50 mg |
For products included in the 2013/14 and 2014/15 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.